CD274 and non-small cell lung carcinoma: Clinical testing of oleclumab with or without durvalumab was initiated in patient populations known to be unresponsive to anti-PD-(L)1 therapies: advanced pancreatic cancer, MSS colorectal cancer, and EGFR mutant non-small cell lung cancer (NCT02503774).